News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Janssen-Cilag International NV Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs
June 14, 2017
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
Pipeline
Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
August 14, 2025
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study
August 14, 2025
·
2 min read
·
Tristan Manalac
